Treatment of psoriasis - new small molecules.
This is a modified version of my invited lecture at the EADV Virtual Congress in 2020.
Currently, the only new molecule approved for psoriasis is apremilast.
This presentation focuses on drugs with are under development, including
JAK inhibitors, such as tofacitinib (trade names Xeljanz/Jakvinus) against JAK3 and 1 approved for psoriatic arthritis and rheumatoid arthritis; ruxolitinib (trade names Jakafi/Jakavi) against JAK1/JAK2 approved for hematological diseases and baricitinib (trade name Olumiant) against JAK1/JAK2, approved for rheumatoid arthritis.
Other new small molecules, such as PDE4 inhibitors and Bruton kinase inhibitors are currenly inverstigated.
#NotJustHairDiseases #ProfLidiaRudnicka
Treatment of psoriasis - new small molecules
Теги
psoriasis treatmentpsoriasis new drugspsoriasis tofacitinibpsoriasis small moleculespsoriasis baricitinibpsoriasis jak inhibitorsRuxolitinib psoriasissmall molecules examplesjanus kinase inhibitors in dermatologysmall molecules in dermatlogysystemic small moleculestopical small moleculessmall molecules adverse effectsjak inhibitors side effectstofacitinib side effectstofacitinib for psoriatic arthritispsoriatic arthritis treatmenttofacitinib
